Plasma selenium level before diagnosis and the risk of prostate cancer development

James D. Brooks, E. Metter, Daniel W. Chan, Lori J. Sokoll, Patricia Landis, William G. Nelson, Denis Muller, Reubin Andres, H. Ballentine Carter

Research output: Contribution to journalArticle

209 Citations (Scopus)

Abstract

Purpose: Epidemiological studies and a randomized intervention trial suggest that the risk of prostate cancer may be reduced by selenium intake. We investigated whether plasma selenium level before diagnosis correlated with the risk of later developing prostate cancer. Materials and Methods: A case control study was performed on men from the Baltimore Longitudinal Study of Aging registry, including 52 with known prostate cancer and 96 age matched controls with no detectable prostatic disease. Plasma selenium was measured at an average time plus or minus standard deviation of 3.83 ± 1.85 years before the diagnosis of prostate cancer by graphite furnace atomic absorption spectrophotometry. Adjusted odds ratio and 95% confidence interval were computed with logistic regression. Results: After correcting for years before diagnosis, body mass index, and smoking and alcohol use history, higher selenium was associated with a lower risk of prostate cancer. Compared with the lowest quartile of selenium (range 8.2 to 10.7 μg./dl.), the odds ratios of the second (10.8 to 11.8), third (11.9 to 13.2) and fourth (13.3 to 18.2) quartiles were 0.15 (95% confidence interval 0.05 to 0.50), 0.21 (0.07 to 0.68) and 0.24 (0.08 to 0.77, respectively, p =0.01). Furthermore, plasma selenium decreased significantly with patient age (p <0.001). Conclusions: Low plasma selenium is associated with a 4 to 5-fold increased risk of prostate cancer. These results support the hypothesis that supplemental selenium may reduce the risk of prostate cancer. Because plasma selenium decreases with patient age, supplementation may be particularly beneficial to older men.

Original languageEnglish (US)
Pages (from-to)2034-2038
Number of pages5
JournalJournal of Urology
Volume166
Issue number6
DOIs
StatePublished - Jan 1 2001
Externally publishedYes

Fingerprint

Selenium
Prostatic Neoplasms
Odds Ratio
Prostatic Diseases
Confidence Intervals
Atomic Spectrophotometry
Baltimore
Graphite
Longitudinal Studies
Registries
Case-Control Studies
Epidemiologic Studies
Body Mass Index
Logistic Models
Smoking
History
Alcohols

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Brooks, J. D., Metter, E., Chan, D. W., Sokoll, L. J., Landis, P., Nelson, W. G., ... Carter, H. B. (2001). Plasma selenium level before diagnosis and the risk of prostate cancer development. Journal of Urology, 166(6), 2034-2038. https://doi.org/10.1016/S0022-5347(05)65500-0

Plasma selenium level before diagnosis and the risk of prostate cancer development. / Brooks, James D.; Metter, E.; Chan, Daniel W.; Sokoll, Lori J.; Landis, Patricia; Nelson, William G.; Muller, Denis; Andres, Reubin; Carter, H. Ballentine.

In: Journal of Urology, Vol. 166, No. 6, 01.01.2001, p. 2034-2038.

Research output: Contribution to journalArticle

Brooks, JD, Metter, E, Chan, DW, Sokoll, LJ, Landis, P, Nelson, WG, Muller, D, Andres, R & Carter, HB 2001, 'Plasma selenium level before diagnosis and the risk of prostate cancer development', Journal of Urology, vol. 166, no. 6, pp. 2034-2038. https://doi.org/10.1016/S0022-5347(05)65500-0
Brooks, James D. ; Metter, E. ; Chan, Daniel W. ; Sokoll, Lori J. ; Landis, Patricia ; Nelson, William G. ; Muller, Denis ; Andres, Reubin ; Carter, H. Ballentine. / Plasma selenium level before diagnosis and the risk of prostate cancer development. In: Journal of Urology. 2001 ; Vol. 166, No. 6. pp. 2034-2038.
@article{9ea23247bbfe479cbbd94187a8db0dab,
title = "Plasma selenium level before diagnosis and the risk of prostate cancer development",
abstract = "Purpose: Epidemiological studies and a randomized intervention trial suggest that the risk of prostate cancer may be reduced by selenium intake. We investigated whether plasma selenium level before diagnosis correlated with the risk of later developing prostate cancer. Materials and Methods: A case control study was performed on men from the Baltimore Longitudinal Study of Aging registry, including 52 with known prostate cancer and 96 age matched controls with no detectable prostatic disease. Plasma selenium was measured at an average time plus or minus standard deviation of 3.83 ± 1.85 years before the diagnosis of prostate cancer by graphite furnace atomic absorption spectrophotometry. Adjusted odds ratio and 95{\%} confidence interval were computed with logistic regression. Results: After correcting for years before diagnosis, body mass index, and smoking and alcohol use history, higher selenium was associated with a lower risk of prostate cancer. Compared with the lowest quartile of selenium (range 8.2 to 10.7 μg./dl.), the odds ratios of the second (10.8 to 11.8), third (11.9 to 13.2) and fourth (13.3 to 18.2) quartiles were 0.15 (95{\%} confidence interval 0.05 to 0.50), 0.21 (0.07 to 0.68) and 0.24 (0.08 to 0.77, respectively, p =0.01). Furthermore, plasma selenium decreased significantly with patient age (p <0.001). Conclusions: Low plasma selenium is associated with a 4 to 5-fold increased risk of prostate cancer. These results support the hypothesis that supplemental selenium may reduce the risk of prostate cancer. Because plasma selenium decreases with patient age, supplementation may be particularly beneficial to older men.",
author = "Brooks, {James D.} and E. Metter and Chan, {Daniel W.} and Sokoll, {Lori J.} and Patricia Landis and Nelson, {William G.} and Denis Muller and Reubin Andres and Carter, {H. Ballentine}",
year = "2001",
month = "1",
day = "1",
doi = "10.1016/S0022-5347(05)65500-0",
language = "English (US)",
volume = "166",
pages = "2034--2038",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Plasma selenium level before diagnosis and the risk of prostate cancer development

AU - Brooks, James D.

AU - Metter, E.

AU - Chan, Daniel W.

AU - Sokoll, Lori J.

AU - Landis, Patricia

AU - Nelson, William G.

AU - Muller, Denis

AU - Andres, Reubin

AU - Carter, H. Ballentine

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Purpose: Epidemiological studies and a randomized intervention trial suggest that the risk of prostate cancer may be reduced by selenium intake. We investigated whether plasma selenium level before diagnosis correlated with the risk of later developing prostate cancer. Materials and Methods: A case control study was performed on men from the Baltimore Longitudinal Study of Aging registry, including 52 with known prostate cancer and 96 age matched controls with no detectable prostatic disease. Plasma selenium was measured at an average time plus or minus standard deviation of 3.83 ± 1.85 years before the diagnosis of prostate cancer by graphite furnace atomic absorption spectrophotometry. Adjusted odds ratio and 95% confidence interval were computed with logistic regression. Results: After correcting for years before diagnosis, body mass index, and smoking and alcohol use history, higher selenium was associated with a lower risk of prostate cancer. Compared with the lowest quartile of selenium (range 8.2 to 10.7 μg./dl.), the odds ratios of the second (10.8 to 11.8), third (11.9 to 13.2) and fourth (13.3 to 18.2) quartiles were 0.15 (95% confidence interval 0.05 to 0.50), 0.21 (0.07 to 0.68) and 0.24 (0.08 to 0.77, respectively, p =0.01). Furthermore, plasma selenium decreased significantly with patient age (p <0.001). Conclusions: Low plasma selenium is associated with a 4 to 5-fold increased risk of prostate cancer. These results support the hypothesis that supplemental selenium may reduce the risk of prostate cancer. Because plasma selenium decreases with patient age, supplementation may be particularly beneficial to older men.

AB - Purpose: Epidemiological studies and a randomized intervention trial suggest that the risk of prostate cancer may be reduced by selenium intake. We investigated whether plasma selenium level before diagnosis correlated with the risk of later developing prostate cancer. Materials and Methods: A case control study was performed on men from the Baltimore Longitudinal Study of Aging registry, including 52 with known prostate cancer and 96 age matched controls with no detectable prostatic disease. Plasma selenium was measured at an average time plus or minus standard deviation of 3.83 ± 1.85 years before the diagnosis of prostate cancer by graphite furnace atomic absorption spectrophotometry. Adjusted odds ratio and 95% confidence interval were computed with logistic regression. Results: After correcting for years before diagnosis, body mass index, and smoking and alcohol use history, higher selenium was associated with a lower risk of prostate cancer. Compared with the lowest quartile of selenium (range 8.2 to 10.7 μg./dl.), the odds ratios of the second (10.8 to 11.8), third (11.9 to 13.2) and fourth (13.3 to 18.2) quartiles were 0.15 (95% confidence interval 0.05 to 0.50), 0.21 (0.07 to 0.68) and 0.24 (0.08 to 0.77, respectively, p =0.01). Furthermore, plasma selenium decreased significantly with patient age (p <0.001). Conclusions: Low plasma selenium is associated with a 4 to 5-fold increased risk of prostate cancer. These results support the hypothesis that supplemental selenium may reduce the risk of prostate cancer. Because plasma selenium decreases with patient age, supplementation may be particularly beneficial to older men.

UR - http://www.scopus.com/inward/record.url?scp=0035174360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035174360&partnerID=8YFLogxK

U2 - 10.1016/S0022-5347(05)65500-0

DO - 10.1016/S0022-5347(05)65500-0

M3 - Article

VL - 166

SP - 2034

EP - 2038

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 6

ER -